title: [Effects of budesonide, desloratadine and dexamethasone on interleukine-4 release and expression from human mast cell line].
abstract: OBJECTIVE
  Since human mast cell is an important source of cytokines, it is of importance to understand the effects of anti-allergic drugs on cytokines modulation in mast cells. In the present study, we aimed at observing whether IL-4 could be released from human mast cell line (HMC-1) after the stimulation of PMA + A23187, and the effects of systemic glucocorticosteroid, dexamethasone, topical glucocorticosteroid, budesonide and H1 antagonist, desloratadine on IL-4 release and mRNA expression.
  
  
  METHODS
  HMC-1 was stimulated with 25 ng/ml phorbol 12-myristate 13-acetate (PMA) and 2.5 x 10(-7) mol/L ionomycin (A23187) and cultured for 6 hours, 12 hours and 24 hours respectively in the presence or absence of 10(-6)-10(-10) mol/L concentrations of test drugs. Culture supernatants were collected and the levels of IL-4 were assayed by enzyme-linked immunosorbent assays (ELISA). The mRNA expression of IL-4 was measured by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR).
  
  
  RESULTS
  HMC-1 expressed IL-4 mRNA and the resulting protein production of IL-4 released after being stimulated with PMA plus A23187. Dexamethasone, budesonide and desloratadine had potent inhibitory effect on IL-4 release at any concentrations and time points, with significant deference (P < 0.05) compared to the control cells. The inhibitory effect did not show time-dependent and concentration-dependent manner. Desloratadine and budesonide showed neither up-regulatory nor down-regulatory effects on IL-4 mRNA expression at the test concentrations, however, desloratadine could down-regulate IL-4 mRNA expression.
  
  
  CONCLUSIONS
  HMC-1 could express and produce IL4 after stimulation. Dexamethasone, budesonide and desloratadine all had inhibitory effects on IL-4 release from HMC-1. In addition, desloratadine could also inhibit the IL-4 mRNA expression.
authors.affiliation: Department of Otorhinolaryngology, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, N T, Hong Kong SAR, China. zhaoyu@surgery.cuhk.edu.hk
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhao
authors.forename: C Andrew
authors.initials: CA
authors.lastname: van Hasselt
authors.forename: Kang-Sang
authors.initials: KS
authors.lastname: Woo
authors.forename: Yeuk-Oi
authors.initials: YO
authors.lastname: Wong
authors.forename: Chuan-Yu
authors.initials: CY
authors.lastname: Liang
authors.forename: Ping-Chung
authors.initials: PC
authors.lastname: Leung
mesh_terms: D019819:Budesonide / Q000494:pharmacology*; D002460:Cell Line; D003907:Dexamethasone / Q000494:pharmacology*; D006801:Humans; D015847:Interleukin-4 / Q000096:biosynthesis*; D017336:Loratadine / Q000031:analogs & derivatives* / Q000494:pharmacology; D008407:Mast Cells / Q000187:drug effects* / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
chemical_list: C508598:IL4 protein, human; D015847:Interleukin-4; D019819:Budesonide; D017336:Loratadine; D003907:Dexamethasone; C121345:desloratadine; D013755:Tetradecanoylphorbol Acetate